Carcinoma, Non-Small-Cell Lung: all 6,641 studies

Page 2 of 67. Open to participants first (1,665), then studies with results posted, then the rest; newest registration first within each.

• Adjuvant Immune Checkpoint Inhibitor Versus Observation After Neoadjuvant Immunochemotherapy and Surgery in High-Risk NSCLCRecruitingNCT07748325Phase 2
• Adaptive Chemotherapy for Pd-l1 High REsEctablE NSCLC: A Chemo-PHREE TrialNot yet recruitingNCT07746388Phase 2
• A Study of IOV-5001 in Adults With Advanced Solid TumorsNot yet recruitingNCT07743723Phase 1/2
• Health for Hungary (H4H) - Longitudinal Collection of Blood Samples and Corresponding DataRecruitingNCT07743021
• Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of ALK201 for Injection in Combination With Ivonescimab Injection in sqNSCLC Participants.Not yet recruitingNCT07742956Phase 2
• Multi-Omics Prediction of Radiation Lung Injury in Immunotherapy-Treated Lung Cancer PatientsNot yet recruitingNCT07742800
• Targeted Induction Therapy for Stage III Unresectable EGFR Mutant Positive NSCLCRecruitingNCT07742332Phase 2
• Study of Robotic Assisted/Image Guided Electromagnetic Navigation Bronchoscopic Therapies and Surgery in Stage IA NSCLCNot yet recruitingNCT07741344Phase 2
• A Study of DS-3939a in Participants With Solid TumorsNot yet recruitingNCT07739966Phase 1/2
• Bronchial Artery Chemoembolization (BACE) Combination Therapy for Advanced NSCLCEnrolling by invitationNCT07738367Phase 2
• Osimertinib With or Without Primary Lung Tumor Resection for EGFR-Mutant Oligometastatic Non-Small Cell Lung CancerRecruitingNCT07738172Phase 3
• Rehabilitation With Wearable Monitors for Post-Lung Cancer SurgeryNot yet recruitingNCT07733492Not applicable
• Navigation Bronchoscopy Guided Microwave Ablation Versus SBRT in Early NSCLCNot yet recruitingNCT07722182Phase 2
• Cemiplimab for Clinical Stage I, 2-3.9cm, Non-Small Cell Lung CancerNot yet recruitingNCT07720167Phase 2
• Global, Multicenter Study of AMT-116 Versus Investigator's Choice in Participants With Advanced or Metastatic Non-squamous EGFR-Wildtype Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 ImmunotherapyNot yet recruitingNCT07718737Phase 2/3
• Investigating the Combination of Bexmarilimab and Nivolumab in Solid Tumours, Melanoma and NSCLCRecruitingNCT07718243Phase 1/2
• Nurse-Led Caregiver Support for Older Adults With Advanced Lung CancerRecruitingNCT07708870Not applicable
• A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid TumorsRecruitingNCT07705334Phase 1
• Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid TumorsRecruitingNCT07704658Phase 4
• First-line Therapy With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor(EGFR-TKI) Combined With Trastuzumab Rezetecan for Advanced Non-small Cell Lung Cancer(NSCLC) Harboring EGFR Mutations Concomitant With Human Epidermal Growth Factor Receptor 2(HER2) AlterationsNot yet recruitingNCT07699952Phase 2
• HSK41959 With Standard Therapy in Solid Tumors With MTAP DeletionNot yet recruitingNCT07699757Phase 1
• A Study of VRN110755 in Patients With EGFR-Mutant Non-Small Cell Lung CancerRecruitingNCT07699328Phase 1/2
• Segmentectomy Versus Lobectomy for Deep Solid-Dominant Early-Stage NSCLCNot yet recruitingNCT07698990Not applicable
• In Vitro NSCLC EGFR-Mutant Models for Drug Sensitivity TestingNot yet recruitingNCT07697716
• Efficacy and Safety of Ivonescimab Monotherapy as First-Line Treatment for PD-L1-Positive, Driver Gene-Negative, Locally Advanced or Metastatic NSCLC: A Multicenter, Prospective, Real-World Cohort StudyRecruitingNCT07696832
• A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced / Metastatic Solid Tumors.Not yet recruitingNCT07689812Not applicable
• ctDNA-Guided Intraventricular Therapy for CNS MalignanciesNot yet recruitingNCT07689721Not applicable
• Safety and Preliminary Efficacy of [177Lu]Lu-RTX-2358 Combined With Immune Checkpoint Inhibitors in Patients With FAP-positive Metastatic Non-Small Cell Lung CancerRecruitingNCT07689643Early Phase 1
• XTX501 in Patients With Metastatic Non-Small Cell Lung Cancer and Advanced Solid TumorsNot yet recruitingNCT07688577Phase 1/2
• A Non-interventional, Real-world Study on the Adjuvant Treatment of Chinese EGFR-positive Stage IA NSCLC Patients With High-risk Factors Using Third-generation EGFR-TKIs.Not yet recruitingNCT07686185
• A Real World Study of Participants With Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor Mutation (EGFRm)Not yet recruitingNCT07680907
• Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)RecruitingNCT07680790Phase 3
• A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)RecruitingNCT07680764Phase 2
• GCC 2545- Improving Post-Radiotherapy Respiratory Function Through Sparing Serial and Parallel Components in the LungNot yet recruitingNCT07679607Phase 2
• Management Strategy of 1L Lorlatinib With Hyperlipidemia in Stage IIIB-IV ALK Positive NSCLCNot yet recruitingNCT07674524
• Clinical Utility of ctDNA in Detecting Resistance Mechanisms and Delivering Precision Medicine to Cancer PatientsRecruitingNCT07673861Not applicable
• A Study of SYS6010 Plus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therapy in Non-small Cell Lung Cancer (NSCLC)Not yet recruitingNCT07672223Phase 3
• Imaging Study in Metastatic UC, HR+ and HER2- Breast Cancer, TNBC, and NSCLCRecruitingNCT07671092Early Phase 1
• Evaluation of XYA02 in Patients With Advanced Solid TumorsRecruitingNCT07670312Phase 1/2
• A Study to Evaluate GFH375 Versus Docetaxel in Participants With Non-Small Cell Lung Cancer With KRAS G12D MutationRecruitingNCT07668752Phase 3
• Characterization of Multi-Omics Landscapes and AI Pathological Prediction Model for Long-Term Survival in NSCLC ImmunotherapyRecruitingNCT07668037
• A Study to Learn About the Study Medicine Called Ponsegromab in Adults With Lung Cancer-Associated Significant Body Weight LossNot yet recruitingNCT07663630Phase 1
• SYHX2011 in Combination With Carboplatin and Enlonstobart as First-Line Therapy for Squamous Non-Small Cell Lung CancerNot yet recruitingNCT07662811Phase 2/3
• SCTB41 Combined With Chemotherapy in Advanced Squamous Non-Small Cell Lung CancerRecruitingNCT07662395Phase 2/3
• Bright Light Therapy in Patients With Melanoma or Non-small Cell Lung Cancer (NSCLC) Who Are Receiving First-Line Immune Checkpoint BlockadeRecruitingNCT07661966Not applicable
• ITTACA (Immunotherapy Time Teller for Advanced Lung Cancer)Not yet recruitingNCT07661251
• A Prospective Study of Firmonertinib as First-line Adaptive Therapy Guided by Dynamic ctDNA (MRD) Changes in Locally Advanced or Metastatic EGFR-mutated Non-small Cell Lung CancerNot yet recruitingNCT07661173Phase 2
• Aglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA)RecruitingNCT07660094Phase 3
• Study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in Patients With Solid TumorsRecruitingNCT07660055Phase 1
• A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung CancerRecruitingNCT07659782Phase 2
• Vebreltinib Plus Furmonertinib in Patients With EGFR-mutated Advanced Non-small Cell Lung Cancer and High PD-L1 ExpressionRecruitingNCT07655622Phase 1/2
• In Vivo Fluorescence Molecular Bronchoscopy of Durvalumab-680LT in Patients With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) After ChemoradiotherapyNot yet recruitingNCT07653438Phase 2
• A Study of CLSP 5282 in HLA-A*03:01 Positive Adult Patients With Solid Tumors (SENTINEL-101)Not yet recruitingNCT07650357Phase 1
• Impact of Liquid Biopsy on the Therapeutic Pathway for Lung Cancer: Advancing the Molecular Characterization of Patients With Advanced Lung Adenocarcinoma by Integrating Liquid Biopsy Into the Early Stages of the Diagnostic and Therapeutic PathwayRecruitingNCT07649629
• Study of SNH-118110 in Advanced Solid TumorsNot yet recruitingNCT07649200Phase 1
• A Prospective, Multicenter, Randomized Controlled Study on the Efficacy and Safety of Low-dose Carboplatin Combined With Nab-Paclitaxel and Delayed Administration of Serplulimab as First-line Treatment for Advanced Squamous Non-small Cell Lung CancerRecruitingNCT07647094Phase 2
• Acute Effects of Visual Feedback-Assisted Inspiratory Muscle Training After LobectomyRecruitingNCT07646288Not applicable
• A Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU-Lung09)RecruitingNCT07642024Phase 2/3
• Dual-Target CAR-NK Cells Targeting MSLN, EGFR, or HER2 in Advanced NSCLCRecruitingNCT07641023Phase 1/2
• A Study Comparing BL-B01D1 in Combination With Osimertinib Versus Osimertinib Alone in Patients With Locally Advanced, Unresectable EGFR-mutated Non-small Cell Lung Cancer(Stage III) Whose Disease Has Not Progressed Following Definitive Platinum-based Chemoradiation Therapy(PANKU-Lung08)RecruitingNCT07640789Phase 3
• Immune Metabolism Dysregulation and Efficacy to Anti-PD-1 PD-L1 Agents in Non Small Cell Lung Cancer PatientsRecruitingNCT07637474
• EGFR-TKIs Plus PD-1 in EGFR-Mutant Advanced NSCLCRecruitingNCT07637448Phase 2
• A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid TumorsRecruitingNCT07636785Phase 1/2
• SYS6010 Combined With Enlonstobart Versus Immunotherapy+ Platinum-based Chemotherapy for Patients With PD-L1-Positive Locally Advanced or Metastatic NSCLC（SYNSTAR 04）Not yet recruitingNCT07633873Phase 3
• Vortioxetine for Cognitive Function in ALK-positive NSCLC Treated With LorlatinibRecruitingNCT07633626
• Pharmacokinetic Study of Pembrolizumab and Its Impact on Immunity and the Tumor Microenvironment, Which May Explain the Efficacy of Post-immunotherapy Chemotherapy.Not yet recruitingNCT07633613Phase 4
• Induction Chemoimmunotherapy in Combination With Chemoradiotherapy and Consolidation Immunotherapy in Unresectable Locally Advanced Non-Small Cell Lung CancerRecruitingNCT07632365Phase 1/2
• Exploratory Study on the Efficacy and Safety of Trastuzumab Rezetecan in the Treatment of HER2-Expressiong Advanced Solid TumorNot yet recruitingNCT07631884Phase 2
• Single-Center Intelligent Pulmonary Rehabilitation After Lung Cancer SurgeryNot yet recruitingNCT07631533Not applicable
• Intelligent Pulmonary Rehabilitation After Lung Cancer SurgeryNot yet recruitingNCT07631520Not applicable
• Nebulized AER101 in Pre-op NSCLCNot yet recruitingNCT07631299Early Phase 1
• Phase I Study of JFI447 [68Ga]Ga-DFC413 and Comparison to FFG233 [68Ga]Ga-NNS309 in Patients With Solid TumorsRecruitingNCT07630961Phase 1
• Effects of Infusion Timing on Treatment Response in Solid TumorsRecruitingNCT07630168Phase 2
• Trastuzumab Rezetecan(SHR-A1811) Combined With Ivonescimab (AK112) in Locally Advanced or Metastatic Non-small Cell Lung Cancer Harboring HER2 Gene AbnormalitiesNot yet recruitingNCT07630077Phase 2
• A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS MutationsRecruitingNCT07629960Phase 1/2
• Standardization of a Platform of Preclinical Models Derived From NSCLC PatientsRecruitingNCT07629375
• Becotatug Vedotin Combined With Pucotenlimab ± Radiotherapy as First-Line Treatment for Driver-Gene-Negative, EGFR-Expression-Positive Advanced Non-Small Cell Lung CancerNot yet recruitingNCT07627321Phase 2
• Evaluating the Efficacy and Safety of AI Localization Models in Multidisciplinary Team Care for NSCLCRecruitingNCT07626736Not applicable
• Study of LT-010391 in Participants With KRAS G12D-Mutant Solid TumorsNot yet recruitingNCT07624214Phase 1
• A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.Not yet recruitingNCT07623642Phase 2
• A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid TumorsRecruitingNCT07623369Phase 1
• A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Non-Small Cell Lung CancerRecruitingNCT07623356Phase 1/2
• A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)RecruitingNCT07622186Phase 2
• SHR-1701 for Induction and Consolidation Therapy in Unresectable Stage III Non-Small Cell Lung CancerNot yet recruitingNCT07619911Phase 2
• A PET Imaging Agent (64Cu-DOTA-Pembrolizumab) for Determining Treatment Response Among Patients With Stage IV Non-small Cell Lung Cancer Receiving PembrolizumabRecruitingNCT07619599Phase 1
• A Study of Tepotinib and Ivonescimab in People With Non-Small Cell Lung CancerRecruitingNCT07619339Phase 1
• Intermittent Hypoxic Training as Neoadjuvant Therapy for Lung Squamous Cell CarcinomaNot yet recruitingNCT07618793Phase 2
• A Study of MET Concordance and Gene Profiling in 1L NSCLC (Genomet)RecruitingNCT07613424Not applicable
• Study on the Mechanism of ADC Drug Evaluation Based on Immune Co-culture of Lung Cancer OrganoidsRecruitingNCT07610616
• A Clinical Study of SCTB41 Combined With Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer（Phase II Study Ongoing）Not yet recruitingNCT07609251Phase 2
• Hypofractionated Chemoradiotherapy With Tislelizumab and Surufatinib for Unresectable Stage III NSCLCRecruitingNCT07609121Phase 2
• IMMUNO-LUNG : Identification of Biomarkers and Therapeutic Targets for Pulmonary ImmunotherapyRecruitingNCT07608835Not applicable
• Neoadjuvant SF-SBRT Plus Toripalimab and Chemotherapy in Resectable Stage II-III NSCLC.Not yet recruitingNCT07608159Phase 3
• A Study Evaluating The Combination of Immunotherapy With Radiotherapy in Non-Small Cell Lung CancerRecruitingNCT07603856Phase 2
• Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of ALK202 for Injection in Combination With Drugs in NSCLC Participants.Not yet recruitingNCT07603791Phase 2
• Sintilimab Plus Chemotherapy as Induction Therapy for Unresectable Stage IIIC NSCLCNot yet recruitingNCT07603661Phase 2
• An EAP Treatment Protocol of ZipalertinibAvailableNCT07601399
• Oral Paclitaxel as Neoadjuvant Therapy in Elderly NSCLC: A Phase II TrialNot yet recruitingNCT07599163Not applicable
• Repotrectinib Post-Marketing Surveillance in Korean Patients With ROS1-Positive Non-Small Cell Lung Cancer (NSCLC) or Solid Tumors Harboring a Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene FusionNot yet recruitingNCT07599007
• Universal Immunization to Fortify Immunotherapy Efficacy and ResponseNot yet recruitingNCT07597070Phase 2

← Carcinoma, Non-Small-Cell Lung overview